At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.
|Articles|April 17, 2020
Quiz: Evolving Treatment Options in BRAF V600E Mutant Metastatic Colorectal Cancer
Author(s)Hannah Slater
In our gastrointestinal cancer quiz, you’ll get a chance to test your knowledge on the BRAF V600E mutation in patients with colorectal cancer.
Advertisement
In our gastrointestinal cancer quiz, you’ll get a chance to test your knowledge on the BRAF V600E mutation in patients with colorectal cancer. Here’s your first question:
1. What combination treatment was studied in the BEACON CRC study of patients with BRAF V600E mutated metastatic colorectal cancer?
A. Encorafenib (Braftovi), cetuximab (Erbitux), and binimetinib (Mektovi)
B. Vemurafenib (Zelboraf), dabrafenib, and trametinib
C. Dabrafenib, cetuximab, and encorafenib
D. Vemurafenib, trametinib, and binimetinib
Advertisement
Related to this article
At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.
At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.
Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
In the VERIFY trial, rusfertide produced a clinical response in 77% of phlebotomy-dependent patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
2
Changing Mindsets and Removing Guilt Surrounding Lung Cancer Diagnoses
3
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
4
Closing the Gap Between Tumor Board Recommendations and Liver Cancer Care
5